Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy

Key Inclusion Criteria: * Male or female between the ages of 12 to 17 * Weight more than 40kg * Undergoing colonoscopy for routinely accepted indications * If female, and of child-bearing potential, subject must use an acceptable form of birth control or remain abstinent for the duration of the study. * Negative pregnancy test at screening, if applicable * In the Investigator's judgment, caregiver is mentally competent to provide informed consent for their child to participate in the study. Exclusion Criteria: * Subjects with known or suspected ileus, impaction, severe ulcerative colitis, acute peritonitis, gastrointestinal obstruction, gastric retention (gastroparesis), bowel perforation, toxic colitis or megacolon. * Subjects who had previous significant gastrointestinal surgeries. * Subjects with increased risk of bowel perforation, including connective tissue disorders, toxic dilation of the bowel or recent bowel surgery. * Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results * Subjects with bleeding disorders and/or impaired platelet function, or neutropenia. * Subjects with a prior history of renal, liver or cardiac insufficiency * Subjects required to take any other oral medication within 3 hours of dosing until completion of both doses. * Subjects with impaired consciousness that predisposes them to pulmonary aspiration. * Subjects with tendency for nausea and/or vomiting, or that have known swallowing disorders. * Subjects for whom intake of substances is likely to affect gastrointestinal motility or urinary flow rate. * Subjects undergoing colonoscopy for foreign body removal and/or decompression.